Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Esketamine acts on the N-methyl-D-aspartate receptor (NMDA ... the way high doses of ketamine do. What’s Next Along with treatment-resistant depression, Spravato is approved along with an ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

However, medication involving the anesthetic, ketamine ... antidepressants, Spravato works as a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been ...

Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.

“It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname "Special K".